Elizabeth Eilertsen explains how she opened a practice that aims to put patients at ease and puts their needs first.

Neurogene has a $903M market cap with two phase 1/2 assets, NGN-401 for Rett Syndrome and NGN-101 for CLN5 Batten Disease.

I had a fascinating talk with Arm Senior VP Chris Bergey on the power of AI and the future of on-device processing ...

SHREVEPORT, La. - Veterans Day celebrated on Nov. 11, is a time for Americans to pause, reflect and express our deep ...

LOUISVILLE, Ky. -- A CD70-targeted CAR T-cell therapy for advanced kidney cancer continued to show durable activity in ...